Analysts Set Expectations for ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($1.97) for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). During the same period in the prior year, the business earned ($0.24) earnings per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, November 13th.

Acumen Pharmaceuticals Trading Down 1.1 %

NASDAQ:ABOS opened at $1.73 on Thursday. The company has a market capitalization of $103.94 million, a P/E ratio of -1.25 and a beta of 0.02. The stock’s 50 day moving average price is $1.96 and its 200 day moving average price is $2.46. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. Acumen Pharmaceuticals has a 52 week low of $1.53 and a 52 week high of $5.09.

Institutional Investors Weigh In On Acumen Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Acumen Pharmaceuticals during the 3rd quarter worth about $44,000. American Century Companies Inc. increased its position in Acumen Pharmaceuticals by 31.3% in the 2nd quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock worth $110,000 after buying an additional 10,840 shares during the period. Rhumbline Advisers acquired a new position in shares of Acumen Pharmaceuticals during the second quarter worth approximately $127,000. Murchinson Ltd. bought a new stake in shares of Acumen Pharmaceuticals in the second quarter valued at approximately $136,000. Finally, Barclays PLC boosted its position in shares of Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock valued at $154,000 after acquiring an additional 40,551 shares during the period. 71.01% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Matt Zuga sold 28,902 shares of the firm’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total value of $49,711.44. Following the transaction, the chief financial officer now directly owns 231,744 shares in the company, valued at approximately $398,599.68. This trade represents a 11.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the transaction, the chief executive officer now owns 454,707 shares in the company, valued at $836,660.88. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 131,526 shares of company stock valued at $233,124 over the last quarter. Insiders own 7.10% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.